Ensysce Biosciences, a clinical-stage biotech company, went public via a SPAC merger with Leisure Acquisition, a special purpose acquisition company, in a $207m deal. “The completion of our merger with LACQ is an extraordinary milestone for our company, our employees, and our shareholders. Crucially, we are led by our highly qualified and experienced board and leadership team that is committed to developing safer prescription drug options for both prescribers and patients. Our board and management team’s experience, extensive relationships and access to the public capital markets position us well for the future and we look forward to creating long-term value for all stakeholders," Lynn Kirkpatrick, Ensysce CEO.